CyBio Northern Europ Ltd. and Reactionlab A/S sign distributor agreement

16-Oct-2006

The British subsidiary of CyBio AG, CyBio Northern Europe Ltd. and Reactionlab A/S, Denmark, signed a distributor- and marketing agreement. Reactionlab A/S will be responsible for distribution of CyBio's products in the countries Denmark, Iceland, Finland, Norway and Sweden. According to the company, the new distributor is already well positioned with offices in the afore mentioned countries to represent and strengthen CyBio in the Scandinavian market for Life Science.

Other news from the department business & finance

Most read news

More news from our other portals

So close that even
molecules turn red...

Last viewed contents

QIAGEN Strengthens QIAstat-Dx With New Barcelona Site - Drive Growth in Infectious Diseases and Precision Medicine Testing

QIAGEN Strengthens QIAstat-Dx With New Barcelona Site - Drive Growth in Infectious Diseases and Precision Medicine Testing

Danish biotech company Egalet appoints new chairman and new CEO

Silence Therapeutics Issued New U.S. Patent Covering Fundamental RNA Interference Technology Currently in Several Clinical Trials - New Patent Broadens Company’s Existing Protection of Optimized RNAi Molecules Including Proprietary AtuRNAi Platform

Biofrontera received official review of its drug approval dossier for BF-200 ALA

Acambis extends Sanofi Pasteur licensing agreement on single-dose JE vaccine to India and Indian subcontinent

Exiqon A/S wins prestigious Ernst & Young Entrepreneur of the Year Award

Bio-Rad Announces Receipt of New Ruling in Applied Biosystems Patent Infringement Dispute

Sandoz completes acquisition of EBEWE Pharma, improving global patient access to affordable injectable cancer medicines - Sandoz to focus on quick and seamless integration for customers and employees

Eckert & Ziegler acquires Vitalea Science Inc. as Part of Strategic Move into Innovative Pharmaceutical Services

Albumin preserves kidney function and improves survival in abdominal infection of liver disease

Transition Therapeutics Announces Appointment of Vice-President of Clinical Operations

UCB to sell its U.S. specialty generics business Kremers Urban for US$ 1,525 million